Online citations, reference lists, and bibliographies.
← Back to Search

PET Scan Contribution In Chest Tumor Management: A Systematic Review For Thoracic Surgeons.

Leonardo Duranti, F. Leo, U. Pastorino
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AIMS AND BACKGROUND In the 90s, the introduction of positron emission tomography (PET) represented a milestone in the staging of thoracic tumors. In the last 10 years, PET scan has been widely adopted in thoracic oncology, showing high accuracy in diagnosis and staging and with promising issues in defining prognosis. The aim of this systematic review was to focus on the results and pitfalls of PET scan use in the modern management of chest tumors. METHODS AND STUDY DESIGN The literature search was performed on May 2010 in PubMed, Embase, and Cochrane according to PRISMA protocol. The search was restricted to publications in English, using in the same string the word "PET" with 9 different chest tumors; results were then filtered by eliminating technical articles, focusing only on papers in which surgery was considered as a potential diagnostic or therapeutic tool. From 6600 papers initially selected, 99 manuscripts were fully analyzed. RESULTS Glucose uptake is a metabolic marker useful in the diagnosis and staging of chest tumors. In lung cancer screening, standard uptake value is helpful in defining the risk of malignancy of isolated pulmonary nodules. The addition of PET scan to conventional staging increases detection of nodal and distant metastases in lung cancer, esophageal cancer and malignant mesothelioma. In thymoma, a close relationship between standard uptake value, histology, and Masaoka stage has been advocated. This link between glucose uptake and prognosis suggests that PET translates biological tumor behavior into clinically detectable findings. CONCLUSIONS PET scan has a crucial role in thoracic oncology due to its impact on diagnosis, staging and prognosis. PET scan expresses the biological behavior of tumors, opening interesting perspectives in chest tumor management and improving detection and stage grouping in lung cancer. It anticipates the diagnosis in long-incubating diseases such as mesothelioma and increases biological knowledge of rare diseases, such as thymoma and other mediastinal tumors.
This paper references
10.1016/j.lungcan.2008.11.009
Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons.
H. Lee (2009)
10.1510/icvts.2009.207621
Value of positron emission tomography in full-thickness chest wall resections for malignancies.
D. Petermann (2009)
10.1200/JCO.2005.12.072
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
H. Schöder (2005)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1378/chest.09-2625
Reporting a systematic review.
B. Wieseler (2010)
10.1102/1470-7330.2007.0004
Overview of early response assessment in lymphoma with FDG-PET
M. MacManus (2007)
10.1148/RADIOL.2363041310
Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
S. S. Shim (2005)
10.1200/JCO.2005.02.4695
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
G. J. Herder (2006)
10.1016/j.lungcan.2008.09.006
The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer.
N. Subedi (2009)
10.1111/j.1365-2796.2006.01729.x
Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours
S. Krüger (2006)
10.1016/j.ejcts.2009.03.055
Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses.
L. Luzzi (2009)
10.1001/JAMA.285.7.914
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
M. Gould (2001)
10.2967/jnumed.108.054239
Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors
C. Nahmias (2008)
10.1007/s00259-006-0273-5
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer
S. Eschmann (2006)
10.1016/J.LUNGCAN.2006.09.028
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
S. Eschmann (2007)
10.1016/j.lungcan.2008.01.003
Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors.
M. Endo (2008)
10.1016/j.athoracsur.2008.09.081
Evaluation of semiquantitative assessments of fluorodeoxyglucose uptake on positron emission tomography scans for the diagnosis of pulmonary malignancies 1 to 3 cm in size.
Yasuomi Ohba (2009)
10.1007/s12149-009-0283-z
Characterization of thymic masses using 18F-FDG PET-CT
A. Kumar (2009)
10.1016/j.ejcts.2008.09.007
The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules.
Daniel L C Fortes (2008)
10.1016/J.EJCTS.2007.01.024
Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
H. Elbawab (2007)
10.2214/AJR.182.4.1820971
Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning.
Sylvain Beaulieu (2004)
10.1016/S0022-5223(03)00211-3
Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis.
U. Pastorino (2003)
10.1097/01.MNM.0000237986.31597.86
18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas
A. Iagaru (2006)
10.1023/A:1011111322376
FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT.
C. Franzius (2001)
10.1097/01.MNM.0000171781.11027.BB
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation
P. Castellucci (2005)
10.1088/0031-9155/53/16/001
Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax--a phantom study.
J. Boucek (2008)
10.1055/s-0029-1185733
Prognostic value of 18-FDG uptake in early stage NSCLC.
J-C Chen (2009)
10.1200/JCO.2004.07.188
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
M. de Santis (2004)
10.2214/AJR.06.0503
Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications.
S. Chong (2007)
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
G. Jerusalem (2000)
10.1002/cncr.22292
The role of FDG‐PET/CT in suspected recurrence of breast cancer
L. Radan (2006)
10.1016/J.IJROBP.2005.04.021
The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
H. Ashamalla (2005)
Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.
A. Matthies (2002)
10.2967/jnumed.108.057182
Standards for PET Image Acquisition and Quantitative Data Analysis
R. Boellaard (2009)
10.1016/J.EJCTS.2006.11.056
Suture and stapler granulomas: a word of caution.
M. Yüksel (2007)
10.1016/S0022-5223(97)70397-0
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.
U. Pastorino (1997)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1097/JTO.0b013e3181a99fde
Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG PET/CT for Patients with Advanced/Metastatic Non-small Cell Lung Cancer
D. Lee (2009)
10.1016/J.LUNGCAN.2003.11.007
FDG-PET in staging lung cancer: how does it change the algorithm?
A. Verhagen (2004)
10.1007/s12149-007-0142-8
The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET
Hung-Jen Hsieh (2008)
10.1510/icvts.2008.201251
The maximum standardized 18F-fluorodeoxyglucose uptake on positron emission tomography predicts lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer.
R. Maeda (2009)
10.1097/01.mnm.0000243366.96012.c0
18F-FDG PET imaging in assessing exudative pleural effusions
B. Duysinx (2006)
10.1016/J.JTCVS.2005.08.070
Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study.
R. Cerfolio (2006)
10.1038/bjc.1996.157
PET imaging of primary mediastinal tumours.
K. Kubota (1996)
10.1016/J.LUNGCAN.2004.01.009
Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images.
H. Nomori (2004)
10.1007/s00259-003-1299-6
PET/CT: a new imaging technology in nuclear medicine
H. Schöder (2003)
10.1097/01.rli.0000154217.71461.b4
Differentiation Between Malignant and Benign Pleural Effusion in Patients With Extra-Pleural Primary Malignancies: Assessment With Positron Emission Tomography-Computed Tomography
Jacob S Toaff (2005)
10.1016/S0140-6736(02)08352-6
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial
H. Tinteren (2002)
10.1016/j.surg.2009.04.024
Incidental PET/CT findings in the cancer patient: how should they be managed?
J. S. Beatty (2009)
10.1097/JTO.0b013e3181cbf465
Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma
C. Tan (2010)
10.1097/01.MNM.0000134329.30912.49
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective
G. Lucignani (2004)
10.1378/CHEST.07-1352
Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition).
M. Wahidi (2007)
10.1016/j.lungcan.2009.10.015
The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
Christian Casali (2010)
10.1378/chest.08-3002
Diagnostic utility and clinical application of imaging for pleural space infections.
J. Heffner (2010)
10.1016/J.RADONC.2005.09.016
Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer.
K. Lavrenkov (2005)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1023/A:1008437915860
Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.
J. Vansteenkiste (1998)
10.1016/J.JTCVS.2003.07.030
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
C. Reed (2003)
10.2967/jnumed.108.052712
Diagnosis and Differentiation of Bronchioloalveolar Carcinoma from Adenocarcinoma with Bronchioloalveolar Components with Metabolic and Anatomic Characteristics Using PET/CT
B. Goudarzi (2008)
10.1016/j.athoracsur.2009.05.083
Standard uptake value predicts survival in non-small cell lung cancer.
I. Okereke (2009)
10.1378/CHEST.07-1383
Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
D. Arenberg (2007)
10.1055/S-2004-817844
Lymph node staging in lung cancer using [18F]FDG-PET.
G. Halter (2004)
10.1378/chest.09-2356
PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
V. Nair (2010)
10.1002/cncr.10494
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma
C. Kollmannsberger (2002)
10.1016/J.LUNGCAN.2005.03.007
The role of PET in the surgical management of malignant pleural mesothelioma.
R. Flores (2005)
10.1007/s12149-009-0278-9
11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness
Hidekatsu Shibata (2009)
10.1016/S0140-6736(03)14188-8
Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results
U. Pastorino (2003)
10.1097/COC.0b013e318162f150
PET-CT in Radiation Oncology: The Impact on Diagnosis, Treatment Planning, and Assessment of Treatment Response
D. Heron (2008)
10.1007/s00259-004-1566-1
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
N. Krak (2004)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)
10.1055/s-2008-1039314
The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
A. Orki (2009)
10.1016/S0003-4975(00)01769-0
Factors associated with false-positive staging of lung cancer by positron emission tomography.
P. Roberts (2000)
10.1097/JTO.0b013e3181bbf1dc
Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers
U. Pastorino (2009)
18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.
Y. Sung (2006)
10.1200/JCO.2004.04.126
Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer.
R. Viney (2004)
10.1016/S1010-7940(02)00108-2
Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules.
A. Carretta (2002)
10.1016/J.ATHORACSUR.2004.02.067
The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
R. Cerfolio (2004)
A combined PET/CT scanner for clinical oncology.
T. Beyer (2000)
10.1016/J.IJROBP.2003.10.044
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
J. Bradley (2004)
10.2967/jnumed.109.066639
A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
I. Kayani (2009)
10.1097/JTO.0b013e3180600990
Clinical Stage I Non-small Cell Lung Cancer Including FDG-PET Imaging: Sites and Time to Recurrence
J. Gauger (2007)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1016/J.JTCVS.2003.08.010
The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer.
H. Nomori (2004)
10.1038/sj.bjc.6600262
Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases
G. Veronesi (2002)
10.1378/CHEST.117.3.773
Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small ( 3 cm) lymph node lesions.
N. Gupta (2000)
10.1016/J.JTCVS.2007.01.041
Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
R. Downey (2007)
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
F. Bénard (1999)
10.1007/s002590050291
Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
T. Bury (1998)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1016/j.lungcan.2009.01.009
Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
J. S. Sun (2009)
PET tracers and radiochemistry.
Schlyer Dj (2004)
10.1016/J.ATHORACSUR.2004.07.072
Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size.
H. Nomori (2005)
10.1378/CHEST.06-0711
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
C. Daniels (2007)
10.1016/J.ATHORACSUR.2007.04.058
Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening.
G. Veronesi (2007)
10.1111/j.1754-9485.2009.02058.x
18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma *
R. Subramaniam (2009)
10.1016/S0169-5002(02)00023-5
FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence.
Donita R Croft (2002)
10.1378/CHEST.64.6.700
Operative and pathologic survey of 50 cases of peripheral lung tumors scanned with 67 gallium.
A. Cellerino (1973)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar